Abstract
Experiments were designed to examine whether local cytokine therapy of subcutaneous (s.c.) tumours results in inhibition of their lung metastases. Moderately immunogenic, major histocompatibility complex (MHC) class I and II negative, B7 negative, metastasizing murine carcinoma MK16 transplantable in syngeneic mice was obtained by co-transfection of human papilloma virus type 16 (HPV16) E6/E7 and activated H-ras oncogene plasmid DNA into C57BL/6 kidney cells. After s.c. transplantation of the malignantly converted MK16 cells, the majority of the transplanted mice developed lung metastases; the number and size of the lung metastases increased with the increasing size of the s.c. tumour. Therapy of 5-day MK16 tumours by peritumoral administration of recombinant interleukin-2 (IL-2) and recombinant interleukin-12 (IL-12) inhibited growth of the s.c. MK16 tumour transplants and reduced the number of MK16 lung metastases. To investigate the antimetastatic effect of IL-2 and IL-12 in a clinically more relevant setting, surgical minimal residual tumour disease was utilized. Subcutaneously growing MK16 carcinomas, 8–12 mm in diameter, were removed on day 30 and the operated mice were injected with IL-2 or IL-12 on days 35–39 and 42–46 at the site of the operation. Treatment with IL-2 significantly reduced the percentage of MK16 tumour recurrences as well as the number of lung metastases, whereas the effect of IL-12 was substantially weaker and statistically insignificant.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sedlacek HH. Vaccination for treatment of tumours: A critical comment. Crit Rev Oncogenesis 1994; 5: 555–87.
Bubeník J. Gene transfer for immunotherapy of cancer. Gene Ther 1996; 3: 944–5.
Bubeník J. Genetically engineered dendritic cell-based cancer vaccines. Int J Oncol 2001; 18: 475–8.
Šmahel M, Sobotková E, Bubeník J et al. Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br J Cancer 2001; 84: 374–80.
Bubeník J, Šímová J, Hájková-Mikyšková R et al. Interleukin 2 gene therapy of mice carrying tumours induced by HPV16. Int J Oncol 1999; 14: 593–7.
Bubeník J. Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol Ther 1996; 69: 1–14.
Gately MK, Renzetti LM, Magran J et al. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses. (Review) Annu Rev Immunol 16: 495-521.
Bubeník J, Indrová M, Nemecková S et al. Solubilized tumourassociated antigens of methylcholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph node cells, macrophage electrophoretic mobility assay and transplantation test. Int J Cancer 1978; 21: 348–55.
Rössner P, Bubeník J, Indrová M et al. Genetically modified tumour vaccines: insertion of the IL-2 gene downregulates tumorigenicity more efficiently than insertion of the CD80 gene. Int J Oncol 1997; 10: 77–82.
Shen Z, Reznikoff G, Dranoff G et al. Cloned dendritic cell can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997; 158: 2723–0.
Gillis S, Ferm MM, Ou W et al. T-cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 1978; 120, 2027–32.
Bubeník J, Indrová M, Perlmann P et al. Tumour inhibitory effects of TCGF/IL-2/-containing preparations. Cancer Immunol Immunother 1985; 19, 57–61.
Huang AYC, Golumbek P, Ahmadzadeh M et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961–5.
Matsumoto G, Omi Y, Lee U et al. Adhesion mediated by LFA-1 is required for efficient IL-12-induced NK and NKT cell cytotoxicity. Eur J Immunol 2000; 30: 3723–31.
Anzai R, Seki S, Ogasawara K et al. Interleukin-12 induces cytotoxic NK1+αvβT cells in the lungs of euthymic and athymic mice. Immunology 1996; 88: 82–9.
Takeda K, Seki S, Ogasawara K et al. Liver NK1.1+CD4+αvβT cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J Immunol 1996; 156: 3366–73.
thor Straten P, Guldberg P, Schrama D et al. In situ cytokine therapy: redistribution of clonally expanded T cells. Eur J Immunol 2001; 31: 250–8.
Brunda MJ, Luistro L, Gately MK et al. Antitumour and antimetastatic activity of IL-12 against murine tumors. J Exp Med 1993; 178: 1223–30.
O'Tool M, Wolf SF, O'Brian C. Effect of in vivo IL-12 administration on murine tumor cell growth. J Immunol 1993; 150: 294A.
Tahara H, Zeh HJ, Storkus WJ III. Fibroblasts genetically engineered to secrete IL-12 can supress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182–9.
Nastala CL, Edington HD, Mckinney TG et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994; 153: 1697–706.
Stern LL, Tarby CM, Tamborini B et al. Preclinical development of IL-12 as an anticancer drug: comparison to IL-2 (Abstr 3100). Proc Am Assoc Cancer Res 1994; 35: 520.
Mayor S, O'Donnell M, Clinton SK. Interleukin-12(IL-12) immunotherapy of experimental bladder cancer (Abstr 2827). Proc Am Assoc Cancer Res 1994; 35: 474.
Pulaski BA, Clements VK, Pipeling MR et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ. Cancer Immunol Immunother 2000; 49: 34–5.
Hafner M, Falk W, Echtenacher B et al. Interleukin-12 activates NK cells for IFN-γ-dependent and NKT cells for IFN-γ-independent antimetastatic activity. Eur Cytokine Netw 1999; 4(10): 541–48.
Lindsey KR, Rosenberg SA, Sherry RM. Impact of the number of treatments courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol 2000; 18: 1954–9.
Atkins MB, Kunkel L, Sznol M et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Longterm survival update. Cancer Sci Am 2000; 6 Suppl 1: S11–4.
Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105–16.
Tasaki K, Tagawa M, Gunji Y et al. Inhibition of experimental lung metastasis of murine colon carcinoma cells depends on the amount of interleukin-2 secreted from the transduced cells. Anticancer Res 1998; 18: 813–8.
Vaage J. Local and systemic effects during interleukin-2 therapy of mouse mammary tumors. Cancer Res 1987; 47: 4296–8.
Vaage J, Pauly JL, Harlos JP. Influence of the administration schedule on the therapeutic effect of interleukin-2. Int J Cancer 1987; 39: 530–3.
Mu J, Zou JP, Yamamoto N et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastazising spontaneously to lung and lymph nodes. Cancer Res 1995; 55: 4404–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mikyšková, R., Bubeník, J., Mendoza, L. et al. Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases. Clin Exp Metastasis 18, 581–587 (2000). https://doi.org/10.1023/A:1011987206008
Issue Date:
DOI: https://doi.org/10.1023/A:1011987206008